Literature DB >> 4017288

The role of C1, C1-inactivator and C4 in modulating immune precipitation.

J A Schifferli, G Steiger, M Schapira.   

Abstract

To clarify the mechanism of inhibition of immune precipitation by early components of the classical pathway of complement, aggregation of 125I-BSA-rabbit-anti-BSA antibody complexes was performed in the presence of purified C1, C1-inactivator (C1-In) and C4. C1 delayed the rate of immune precipitation in a concentration dependent manner. This phenomenon was not influenced by the presence of 0.3 mM p-nitrophenyl-p-guanidinobenzoate (NPGB) which inhibits C1 activation. The antiaggregational effect of C1 was reversed by 10 mM EDTA and by C1-In at a C1-In/C1 molar ratio of greater than or equal to 4/1. C1-In was not effective when the reaction was performed in the presence of NPGB. Thus, although the inhibitory effect of C1 on immune precipitation was not dependent upon C1 activation, the formation of C1 was required to observe the effect of C1-In. The addition of C4 to C1 did not modify the slow aggregation of complexes, even when a limiting concentration of C1 was used. C1-In and EDTA were both able to cause similar rapid precipitation of complexes prepared in the presence of C1 and C4, demonstrating that C4 did not play a significant role in delaying the precipitation reaction. However, soluble complexes prepared in the presence of C1 and C4 were specifically precipitated by the addition of excess anti-C4 antibody, attesting to the binding of C4 to immune complexes. These observations suggest that the processing of immune complexes in vivo may not be similar in different classical pathway complement deficiency states.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4017288      PMCID: PMC1577218     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Active disassembly of the first complement component, C-1, by C-1 inactivator.

Authors:  R J Ziccardi; N R Cooper
Journal:  J Immunol       Date:  1979-08       Impact factor: 5.422

2.  Reactions in agarose gel between C1q and aggregated gamma globulin.

Authors:  S Thunold; C J Abeyounis; F Milgrom
Journal:  J Immunol       Date:  1970-03       Impact factor: 5.422

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Fc-mediated immune precipitation. I. A new role of the Fc-portion of IgG.

Authors:  N P Møller
Journal:  Immunology       Date:  1979-11       Impact factor: 7.397

5.  The subunit composition and sedimentation properties of human C1.

Authors:  R J Ziccardi; N R Cooper
Journal:  J Immunol       Date:  1977-06       Impact factor: 5.422

6.  Requirements for the solubilization of immune aggregates by complement. The role of the classical pathway.

Authors:  M Takahashi; S Takahashi; V Brade; V Nussenzweig
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

7.  Cleavage of C2 by C1s into the antigenically distinct fragments C2a and C2b: demonstration of binding of C2b to C4b.

Authors:  S Nagasawa; R M Stroud
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

8.  A new one-step method for the functional assay of the fourth component (C4) of human and guinea pig complement.

Authors:  T A Gaither; D W Alling; M M Frank
Journal:  J Immunol       Date:  1974-08       Impact factor: 5.422

9.  The first component of complement. I. Purification and properties of native C1.

Authors:  R G Medicus; R M Chapuis
Journal:  J Immunol       Date:  1980-07       Impact factor: 5.422

10.  Studies on the mechanism of solubilization of immune precipitates by serum.

Authors:  J Czop; V Nussenzweig
Journal:  J Exp Med       Date:  1976-03-01       Impact factor: 14.307

View more
  6 in total

1.  Complement mediated inhibition of immune precipitation and solubilization generate different concentrations of complement anaphylatoxins (C4a, C3a, C5a).

Authors:  J A Schifferli; G Steiger; J P Paccaud
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

2.  Difference in the biological properties of the two forms of the fourth component of human complement (C4).

Authors:  J A Schifferli; G Steiger; J P Paccaud; A G Sjöholm; G Hauptmann
Journal:  Clin Exp Immunol       Date:  1986-02       Impact factor: 4.330

3.  Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization.

Authors:  J A Schifferli; G Steiger; G Hauptmann; P J Spaeth; A G Sjöholm
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

Review 4.  Complement deficiency and immune complex disease.

Authors:  K A Davies; J A Schifferli; M J Walport
Journal:  Springer Semin Immunopathol       Date:  1994

5.  Recombinant soluble Fc gamma RII inhibits immune complex precipitation.

Authors:  A L Gavin; B D Wines; M S Powell; P M Hogarth
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

6.  Inhibition of immune complex solubilization by sera of patients with membranoproliferative glomerulonephritis.

Authors:  T R Welch; A Kleesattel; L Beischel
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.